SCHEMBL17691164

SCHEMBL17691164

COCCOCCOCCOCCOCCOCCOCCOCCOCCOC(=O)C=Cc1ccc(-c2nc3c(=O)n(CCc4ccccc4)c(=O)n(CCc4ccccc4)c3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2B P29275 8/20 0.44
▸ ADORA3 P0DMS8 4/20 0.44
▸ ADORA2A P29274 3/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ AKR1B10 O60218 4/20 0.41
▸ AKR1B1 P15121 4/20 0.41
▸ MAOB P27338 1/20 0.41
▸ TTR P02766 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ ALOX5 P09917 2/20 0.38
▸ APP P05067 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ EGFR P00533 2/20 0.38
▸ ERBB2 P04626 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049598 1.00 ADORA2B (0.44) ADORA2BADORA3ADORA2AADORA1AKR1B10
SCHEMBL6049595 0.92 ADORA2B (0.52) ADORA2BADORA3ADORA2AADORA1AKR1B10
SCHEMBL6049606 0.91 ADORA2B (0.51) ADORA2BADORA3ADORA2AADORA1
SCHEMBL6049631 0.87 ADORA2B (0.45) ADORA2BADORA3ADORA2AADORA1AKR1B10
SCHEMBL6049688 0.85 ADORA2B (0.45) ADORA2BADORA3ADORA2AADORA1HDAC1
SCHEMBL6553692 0.85 ADORA2B (0.43) ADORA2BADORA3ADORA2AADORA1KDM4E
SCHEMBL6049561 0.85 ADORA2B (0.41) ADORA2BADORA3ADORA2AADORA1EGFR
SCHEMBL6554030 0.85 ADORA2B (0.43) ADORA2BADORA3ADORA2AADORA1ALOX5
SCHEMBL6553594 0.84 ADORA2B (0.40) ADORA2BADORA3ADORA2AADORA1ALDH1A1
SCHEMBL6555325 0.84 ADORA2B (0.60) ADORA2BADORA3ADORA2AADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988399-B2 Bicyclic compounds as ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-06-05 — — US disclosed
US-20160108060-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-04-21 — — US disclosed
US-20160108060-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108060-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ADORA2B 3395/4885ADORA3 2603/4885ADORA2A 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback